# Phase 6 Implementation Report: UI Excellence & Dataset Expansion

## 1. UI Changes
- **Eligible Protocols**: Replaced the indigo badge-based match display with a high-contrast Green "Why This Matched" section using clean bulleted lists.
- **Ineligible Protocols**: Implemented a Red "Why Not Eligible" section that dynamically derives rejection reasons from strict clinical mismatches (Histology, Biomarkers, Stage).
- **Layout**: Maintained professional slate/indigo palette for secondary information while highlighting status-critical sections.

## 2. Explainability Added
- **Positive Rationale**: Shows specifically which clinical factors (e.g., "EGFR Mutant", "Histology: Adenocarcinoma") satisfied the protocol.
- **Negative Rationale**: Explains exactly why a protocol was disqualified (e.g., "Patient histology is incompatible", "Mismatch: ALK Negative").
- **Safety Messaging**: Retained the footer disclaimer emphasizing MDT review and local dataset limitations.

## 3. Clinical Summary Block
- Added a high-grade **Clinical Summary** header to the top of the CDS Advisor.
- Surfaces Diagnosis, Stage/ECOG, and the top 3 Biomarkers in a clean, non-editable executive view for clinical context before reviewing protocol options.

## 4. Protocols Added (by cancer type)
- **Hepatocellular Carcinoma (HCC)**:
  - Atezolizumab + Bevacizumab (1L, Preferred)
  - Durvalumab + Tremelimumab (STRIDE Regimen)
  - Sorafenib / Lenvatinib (TKI options)
- **Melanoma**:
  - Dabrafenib + Trametinib (BRAF V600E Mutant)
  - Nivolumab + Ipilimumab (BRAF Wild-type)
  - PD-1 Monotherapy (Lower fitness option)
- **Esophageal Cancer**:
  - Trastuzumab + Chemo (HER2+ Adenocarcinoma)
  - Nivolumab + Chemo (Squamous, PD-L1 CPS >= 5)

## 5. Safety Check
- **Isolation**: No changes made to the core `protocolMatcher.ts` logic or the `ALL_OF/ANY_OF` rules.
- **Terminology**: Verified absence of "best treatment" or "recommendation" wording. Regimens are referred to as "Options" or "Strategies".
- **Biomarkers**: All new data points use hard thresholds (e.g., "PD-L1 CPS >= 5", "BRAF V600E Mutant").

## 6. Build Result
- `npx tsc --noEmit`: Completed (Unchanged baseline errors in unrelated modules).
- `npm run build`: **Success**. Chunks generated correctly with new clinical data.

## 7. Ready / Not Ready
- **READY**: Phase 6 has successfully expanded the system's clinical breadth and depth while hardening the UI's transparency and adherence to deterministic safety rules.
